A Novel High-Content Screening Assay Identified Belinostat as Protective in a Focal Segmental Glomerulosclerosis-like Zebrafish Model.

Maximilian Schindler Florian Siegerist Tim Lange Stefan SimmSophia-Marie BachMarianne Klawitter Jochen Gehrig Sheraz Gul Nicole Endlich

Published in: Journal of the American Society of Nephrology : JASN (2023)

Using an FSGS-like zebrafish model, we developed a novel in vivo high-content screening assay that identified belinostat and related pan-HDAC inhibitors as potential candidates for treating FSGS.

Keyphrases

high throughput
risk assessment
human health
histone deacetylase